In a report released yesterday, Yigal Nochomovitz from Citi maintained a Hold rating on Galera Therapeutics (GRTX – Research Report), with a price target of $0.25. The company’s shares closed yesterday at $0.21.
Nochomovitz covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Coherus Biosciences, and Aldeyra Therapeutics. According to TipRanks, Nochomovitz has an average return of 7.4% and a 42.13% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Galera Therapeutics with a $0.42 average price target, implying a 100.76% upside from current levels. In a report released on August 17, Piper Sandler also maintained a Hold rating on the stock with a $0.50 price target.
See the top stocks recommended by analysts >>
GRTX market cap is currently $9.03M and has a P/E ratio of -0.09.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
Read More on GRTX:
- Chevron upgraded, SolarEdge downgraded: Wall Street’s top analyst calls
- Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Galera Therapeutics downgraded to Neutral from Buy at Citi
- Galera Therapeutics reports Q2 EPS (48c), consensus (44c)
- Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
